Cargando…

The Importance of Weight Change Experiences for Performance of Diabetes Self-Care: A Patient-Centered Approach to Evaluating Clinical Outcomes in Type 2 Diabetes

INTRODUCTION: The aim of this study was to examine the influence of weight change experiences over time on motivation to perform diabetes self-care behaviors using data from a study of canagliflozin (an agent that inhibits sodium glucose co-transporter 2) versus glimepiride in dual therapy with metf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Traina, Shana B., Slee, April, Woo, Sangsoon, Canovatchel, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674477/ https://www.ncbi.nlm.nih.gov/pubmed/26608510 http://dx.doi.org/10.1007/s13300-015-0145-8

Ejemplares similares

An Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin
por: Traina, Shana B., et al.
Publicado: (2017)

Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials
por: Cai, Jennifer, et al.
Publicado: (2018)

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates
por: John, Mathew, et al.
Publicado: (2016)

A call to action to inform patient‐centred approaches to obesity management: Development of a disease‐illness model
por: Fastenau, John, et al.
Publicado: (2019)

Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin
por: Leiter, Lawrence A., et al.
Publicado: (2016)

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
por: Bays, Harold E, et al.
Publicado: (2014)

The Diabetes Intention, Attitude, and Behavior Questionnaire: evaluation of a brief questionnaire to measure physical activity, dietary control, maintenance of a healthy weight, and psychological antecedents
por: Traina, Shana B, et al.
Publicado: (2016)

Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data
por: Willis, Michael, et al.
Publicado: (2020)

Pragmatic measurement of health satisfaction in people with type 2 diabetes mellitus using the Current Health Satisfaction Questionnaire
por: Traina, Shana B, et al.
Publicado: (2015)

The importance of weight management in type 2 diabetes mellitus
por: Wilding, J P H
Publicado: (2014)

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus
por: Prasanna Kumar, K. M., et al.
Publicado: (2017)

Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
por: Willis, Michael, et al.
Publicado: (2020)

Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus
por: Desai, Mehul, et al.
Publicado: (2017)

Diabetes Self-Management Education; Experience of People with Diabetes
por: Mardanian Dehkordi, Leila, et al.
Publicado: (2017)

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018)

Weight Change in Diabetes and Glycemic and Blood Pressure Control
por: Feldstein, Adrianne C., et al.
Publicado: (2008)

Acute pyelonephritis in diabetes mellitus: Single center experience
por: Kumar, S., et al.
Publicado: (2014)

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515
por: Schernthaner, G, et al.
Publicado: (2013)

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
por: Stenlöf, K, et al.
Publicado: (2013)

Importance of Weight Loss Maintenance and Risk Prediction in the Prevention of Type 2 Diabetes: Analysis of European Diabetes Prevention Study RCT
por: Penn, Linda, et al.
Publicado: (2013)

Impact of diabetes self-management, diabetes management self-efficacy and diabetes knowledge on glycemic control in people with Type 2 Diabetes (T2D): A multi-center study in Thailand
por: Hurst, Cameron P., et al.
Publicado: (2020)

Association of Self-Reported Weight Change and Quality of Life, and Exercise and Weight Management Behaviors Among Adults with Type 2 Diabetes Mellitus: The SHIELD Study
por: Grandy, Susan, et al.
Publicado: (2012)

Relationship between self-reported weight change, educational status, and health-related quality of life in patients with diabetes in Luxembourg
por: Tchicaya, Anastase, et al.
Publicado: (2015)

Estimating meaningful change for The Impact of Weight on Self-Perception (IW-SP) questionnaire among people with type 2 diabetes
por: Gelhorn, Heather L., et al.
Publicado: (2023)

Distorted Self-Perceived Weight Status and Underestimation of Weight Status in Diabetes Mellitus Type 2 Patients
por: Mogre, Victor, et al.
Publicado: (2014)

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
por: Lavalle-González, F. J., et al.
Publicado: (2013)

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial
por: Schernthaner, Guntram, et al.
Publicado: (2013)

No Spillover Effect of the Foreclosure Crisis on Weight Change: The Diabetes Study of Northern California (DISTANCE)
por: Downing, Janelle, et al.
Publicado: (2016)

Diagnosis of monogenic diabetes: 10‐Year experience in a large multi‐ethnic diabetes center
por: Thomas, Ellen RA, et al.
Publicado: (2015)

Presence of Non-Diabetic Kidney Diseases in Biopsy Specimens of Diabetic Patients’ Single Center Experience
por: Janković, Aleksandar, et al.
Publicado: (2023)

Impact of family‐centered tailoring of pediatric diabetes self‐management resources
por: Fiallo‐Scharer, Rosanna, et al.
Publicado: (2019)

Hepatocellular Carcinoma in Diabetic Patients - a Single Center Experience
por: BRAIA, N., et al.
Publicado: (2016)

COVID-19 and Diabetic Ketoacidosis: A Single Center Experience
por: Singh, Balraj, et al.
Publicado: (2021)

Postpregnancy Glycemic Control and Weight Changes in Type 1 Diabetic Women
por: Cyganek, Katarzyna, et al.
Publicado: (2013)

Weight Change and Cardiometabolic Outcomes in Postpartum Women with History of Gestational Diabetes
por: Lim, Siew, et al.
Publicado: (2019)

Diabetes-related weight change in a Canadian First Nation cohort
por: Riediger, ND, et al.
Publicado: (2017)

Depression-related weight change and incident diabetes in a community sample
por: Graham, Eva, et al.
Publicado: (2021)

Importance of family history of diabetes in computing a diabetes risk score in Korean prediabetic population
por: Ustulin, Morena, et al.
Publicado: (2018)

LBSUN211 The Importance Of Early Opportunities To Identify And Treat Prediabetes Or Even Change The Diagnostic Threshold For Diabetes
por: Schwartz, Stanley S, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l5dehf9qep45s7qoju4l9g58ia